

Heterologous bone grafts with preserved collagen: let's clarify!

The production process used by Bioteck SpA to manufacture its bone grafts is Zymo-Teck®.

Zymo-Teck® is a process patented in 2015 and owned by Bioteck SpA (UIBM n. 0001413858), **based on the use** of enzymes, capable of making equine bone tissue completely biocompatible, preserving the mineral component and bone collagen unchanged.

The Zymo-Teck® process **does not use high temperatures or chemical solvents**, and guarantees complete deantigenation of the grafts without altering the bone collagen and mineral component, thus making them a biological matrix that acts as an optimal natural scaffold for to the new bone tissue formation process.

Terminal sterilisation using beta rays (also called accelerated electrons) is capable of com-

pletely eliminating any microbial contamination while optimally preserving the mechanical and biological characteristics of biomaterials.

The Zymo-Teck® process is unique, as it is patented and used exclusively by Bioteck SpA. In fact, no other company can boast using the same process for the production of its bone grafts.

The unique characteristics of Bioteck SpA biomaterials, as well as their safety and efficacy in various applications, are demonstrated by over **500 clinical-scientific publications specifically describing Bioteck SpA devices** (<https://www.bioteckacademy.com/pubblicazioni-scientifiche/>), by over 2,000 surgeries documented in the literature, with follow-ups of up to 13 years, and by over 2,000,000 pieces used in regenerative procedures in more than 70 countries worldwide.

The Bioteck® Management